James Noble, Adaptimmune CEO, to Participate in Upcoming Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
September 22 2017 - 10:00AM
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell
therapy to treat cancer, today announced that James Noble,
Adaptimmune’s Chief Executive Officer, will participate in the
upcoming Leerink Partners Roundtable Series: Rare Disease and
Immuno-oncology on Thursday, September 28, 2017 at 10:30 AM EDT
(3:30 PM BST) in Holmes I/II at the Lotte New York Palace Hotel.
The conference will be webcast live for investors through the
investor section of www.adaptimmune.com and available for a
period of 30 days following the conference.
About AdaptimmuneAdaptimmune is a
clinical-stage biopharmaceutical company focused on the development
of novel cancer immunotherapy products. The Company’s unique SPEAR
(Specific Peptide Enhanced Affinity Receptor) T‑cell platform
enables the engineering of T-cells to target and destroy cancer,
including solid tumors. Adaptimmune has a number of proprietary
clinical programs, and is also developing its NY-ESO SPEAR T-cell
program under a strategic collaboration and license agreement with
GlaxoSmithKline. The Company is located in Philadelphia, USA and
Oxfordshire, U.K. For more information, please visit
http://www.adaptimmune.com
Forward-Looking StatementsThis release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties.
Such risks and uncertainties could cause our actual results to
differ materially from those indicated by such forward-looking
statements, and include, without limitation: the success, cost and
timing of our product development activities and clinical trials
and our ability to successfully advance our TCR therapeutic
candidates through the regulatory and commercialization processes.
For a further description of the risks and uncertainties that could
cause our actual results to differ materially from those expressed
in these forward-looking statements, as well as risks relating to
our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC)
on August 3, 2017, and our other SEC filings. The forward-looking
statements contained in this press release speak only as of the
date the statements were made and we do not undertake any
obligation to update such forward-looking statements to reflect
subsequent events or circumstances.
Adaptimmune Contacts
Investor RelationsJuli P. Miller, Ph.D.T: (215) 825-9310E:
juli.miller@adaptimmune.com
Media RelationsMargaret HenryT: +44 (0)1235 430036 Cell: +44
(0)7710 304249 E: margaret.henry@adaptimmune.com
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adaptimmune Therapeutics (NASDAQ:ADAP)
Historical Stock Chart
From Apr 2023 to Apr 2024